Short Interest in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Drops By 14.9%

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) saw a significant drop in short interest during the month of January. As of January 15th, there was short interest totaling 42,044,430 shares, a drop of 14.9% from the December 31st total of 49,429,420 shares. Currently, 29.9% of the shares of the company are sold short. Based on an average daily volume of 16,240,884 shares, the days-to-cover ratio is presently 2.6 days. Based on an average daily volume of 16,240,884 shares, the days-to-cover ratio is presently 2.6 days. Currently, 29.9% of the shares of the company are sold short.

Insider Activity at SELLAS Life Sciences Group

In other SELLAS Life Sciences Group news, Director Katherine Bach Kalin acquired 63,400 shares of the business’s stock in a transaction that occurred on Wednesday, November 19th. The stock was acquired at an average price of $1.59 per share, with a total value of $100,806.00. Following the transaction, the director owned 104,400 shares of the company’s stock, valued at approximately $165,996. This trade represents a 154.63% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.40% of the company’s stock.

Hedge Funds Weigh In On SELLAS Life Sciences Group

Hedge funds and other institutional investors have recently made changes to their positions in the company. Axxcess Wealth Management LLC bought a new position in SELLAS Life Sciences Group during the third quarter worth about $26,000. BNP Paribas Financial Markets boosted its holdings in shares of SELLAS Life Sciences Group by 89.2% in the third quarter. BNP Paribas Financial Markets now owns 19,724 shares of the company’s stock valued at $32,000 after buying an additional 9,299 shares during the period. Blair William & Co. IL acquired a new position in shares of SELLAS Life Sciences Group in the second quarter valued at approximately $35,000. Concurrent Investment Advisors LLC bought a new stake in shares of SELLAS Life Sciences Group during the fourth quarter worth $38,000. Finally, ProShare Advisors LLC acquired a new stake in shares of SELLAS Life Sciences Group during the second quarter worth $43,000. 17.38% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $7.00.

SELLAS Life Sciences Group Trading Up 4.2%

Shares of SLS traded up $0.17 on Tuesday, reaching $4.14. 3,596,406 shares of the company’s stock were exchanged, compared to its average volume of 10,882,375. SELLAS Life Sciences Group has a 12 month low of $0.95 and a 12 month high of $5.18. The stock has a market capitalization of $589.00 million, a P/E ratio of -14.76 and a beta of 2.26. The business has a 50 day moving average price of $3.08 and a two-hundred day moving average price of $2.22.

SELLAS Life Sciences Group (NASDAQ:SLS) last issued its earnings results on Wednesday, November 12th. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.02. Equities research analysts predict that SELLAS Life Sciences Group will post -0.57 EPS for the current year.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.